# Winning payer and provider adoption
A brilliant diagnostic that no one will pay for is a science project, not a business. Cologuard, the stool-based colorectal cancer screening test from Exact Sciences, is a useful case: it earned FDA approval and a positive national coverage decision from Medicare on the same day in 2014, then a dedicated CPT code. That alignment of clearance, coverage, and coding is the holy trinity of commercialization. Most products never get all three.
This lesson is about the second and third battles: convincing payers to reimburse and providers to adopt. In biotech and medtech, marketing does not end at the prescriber. It ends at the person who signs the check.
Before a therapy or device generates revenue, three separate audiences must say yes.
Payers. These are the entities that pay for care: government programs (Medicare, Medicaid) and commercial insurers (UnitedHealthcare, Aetna, and others). They ask one question: is this worth covering versus what we already pay for?
Providers. Physicians, hospitals, and health systems. They ask: does this fit my workflow, and will I get paid to use it?
P&T committees. The Pharmacy and Therapeutics committee is the group inside a hospital or health plan that decides which drugs go on the formulary (the approved list of covered medications). No formulary placement, no routine use.
Each gatekeeper needs a different pitch. Your job as a marketer is to build the evidence package that speaks to all three.
These three words get used loosely. They are not the same thing.
Coding is the billing language. A CPT code (Current Procedural Terminology, maintained by the American Medical Association) is the five-digit number a provider submits to get paid for a service. Without a code, there is no clean way to bill. New diagnostics often start with a generic or "unlisted" code, which payers routinely deny, before earning a specific one.
Coverage is the payer's policy decision: will we pay for this, for which patients, under what conditions? A coverage decision can be national (a Medicare NCD, or National Coverage Determination) or local (an LCD from a regional Medicare contractor).
Payment is the actual dollar amount tied to the code.
You can have a code and still get no coverage. You can have coverage with a payment rate so low the product loses money. Marketing must track all three and message to the gaps.
The CMS coverage database is a free, public resource where you can read actual NCDs and LCDs. Reading a few real ones teaches you the exact language payers use to say yes or no.
Payers do not buy science. They buy value. The health-economic dossier is the document that translates your clinical data into economic and outcomes terms.
A common structure is the AMCP format, a standardized dossier template from the Academy of Managed Care Pharmacy that many US payers expect. Building to a known template signals seriousness.
Your dossier answers four questions:
1. What is the unmet need? Quantify the population and the cost of the status quo.
2. What does the product do? Clinical efficacy and safety, in payer-relevant endpoints.
3. What does it cost, and what does it offset? This is the heart of the pitch.
4. What is the total impact on the payer's budget?
Frame value as offsets. A diagnostic that catches disease earlier can reduce downstream treatment costs. A device that shortens hospital stays reduces per-episode spend.
Cologuard's economic case, for example, rested on comparison to colonoscopy and on catching cancer earlier, when treatment is cheaper and outcomes are better. The comparison anchor matters: payers evaluate you against the current standard of care, not against nothing.
A useful metric here is the QALY (quality-adjusted life year), a measure combining length and quality of life. In the US, QALY-based thresholds are not binding the way they are in the UK, but the concept still frames "value for money" conversations.
The dossier proves value per patient. The budget-impact model (BIM) answers the payer's real fear: what happens to my total spend next year if I cover this?
A BIM is a spreadsheet, and marketers should understand its logic even if analysts build it.
Annual budget impact =
(eligible members × uptake rate × cost per patient of new product)
minus
(offsetting costs avoided: hospitalizations, procedures, other drugs)The inputs a payer scrutinizes:
A device that costs more per unit but cuts readmissions can still be budget-neutral or better. Show the math over a realistic time horizon (often one to three years, because payers churn members and do not always capture long-term savings).
Once a drug clears the payer's coverage logic, it still needs formulary placement, decided by the P&T committee.
P&T committees are clinical first, economic second. They include pharmacists and physicians. Your pitch must lead with clinical evidence, then layer economics.
What a strong P&T pitch includes:
The best P&T submissions make the committee's decision easy by pre-answering objections. Bring the counterargument to your own weak spots before they raise it.
Vérification des acquis
1. The lesson describes the "holy trinity of commercialization" as the alignment of clearance, coverage, and coding. Why is achieving all three considered so critical?
2. A hospital's Pharmacy and Therapeutics (P&T) committee has declined to add a newly approved drug to its formulary. What is the most direct commercial consequence?
3. The lesson states that in biotech and medtech, marketing 'ends at the person who signs the check.' What core principle does this illustrate?
4. Select ALL correct answers. Which statements accurately distinguish the three gatekeepers (payers, providers, P&T committees) described in the lesson?
Sélectionnez toutes les réponses correctes.
5. Select ALL correct answers. Based on the lesson, which statements about coding and CPT codes are true?
Sélectionnez toutes les réponses correctes.
Reimbursement is not a launch task. It is a multi-year effort that starts during clinical trial design.
Design trials for payers, not just the FDA. The FDA may accept a surrogate endpoint (a lab marker that stands in for a real outcome, like tumor shrinkage). Payers often want the real outcome (survival, fewer hospitalizations). If your pivotal trial only measures the surrogate, you will fight for coverage for years. Build the comparator and the outcome the payer wants into the trial when you can.
Engage payers early. Many companies conduct advisory boards with payers before launch to pressure-test the value story. Some pursue early scientific advice in Europe or payer meetings in the US.
Coordinate the field teams. Medtech and biotech commercial orgs often run separate teams: sales reps who talk to physicians, and market access or reimbursement specialists who talk to payers and help provider offices navigate billing. When a provider says "I would use this but I cannot get paid," that is a market access failure, and marketing owns the fix, often through billing guides and coding hotlines.
Provider adoption needs its own economics. A physician will not adopt a device that loses their practice money per procedure, no matter how good it is. Check that the payment rate covers the provider's cost and effort. This is why the payment leg of the trinity is not optional.
Coverage denials are common on first submission. The playbook: gather real-world evidence, resubmit with stronger economic data, pursue the coding pathway in parallel, and use pilot contracts with a single health system to generate proof. Persistence and evidence, not louder marketing, move payers.